配售事项所得款项净额估计约为港币1.307亿元。 裕承科金(00279)发布公告，于2025年8月29日(交易时段后)，公司与配售代理订立配售协议，据此，公 司同意透过配售代理按尽力基准以配售价每股配售股份港币0.690元向不少于六名承配人配售最多1.91亿 股配售股份。 配售价较于2025年8月29日(即配售协议日期)在联交所所报收市价每股股份港币0.850元折让约18.8%。 ...

募集资金将用于：产品研发与升级，提升技术和解决方案能力。产品商业化及业务发展，加强外部合作 以扩大公司规模和市场份额。潜在的收购投资、人才吸引、营运资金补充及一般公司用途。 晶泰控股公布，公司已与配售代理签订配售协议，计划以每股9.28港元的配售价，配售最多约2.86亿股 股份。若配售成功，公司预计净筹约26.3亿港元。 （文章来源：证券时报网） ...

Core Viewpoint - The company, 科笛-B (02487), has announced a share placement agreement to issue approximately 28.9 million shares at a price of HKD 8.40 per share, representing about 9.05% of its existing shares, with the net proceeds expected to be around HKD 240 million [1] Group 1: Share Placement Details - The placement price of HKD 8.40 per share reflects a discount of approximately 12.04% compared to the closing price of HKD 9.55 on the announcement date [1] - The share placement is facilitated by placement agents who will act on behalf of the company [1] Group 2: Use of Proceeds - Approximately 45% of the net proceeds will be allocated for clinical research and trials related to local fat accumulation management, hair diseases and care, skin diseases and care, and epidermal anesthesia pipeline [1] - Another 45% of the net proceeds will be used for marketing activities, channel expansion, and brand building for CU-40102 (a topical finasteride spray) and CU-10201 (a topical 4% minocycline foam) [1] - The remaining 10% of the net proceeds will be utilized for working capital and other general corporate purposes [1]

Core Viewpoint - The company, 科笛-B (02487), has entered into a placement agreement to issue 28.904 million shares at a price of HKD 8.40 per share, representing approximately 9.05% of the company's issued shares as of the announcement date, with a discount of about 12.04% compared to the closing price of HKD 9.55 on August 28, 2025 [1] Summary by Categories Placement Details - The placement agreement was signed with placement agents on August 28, 2025, to facilitate the subscription of shares at HKD 8.40 each [1] - The total number of shares to be placed is 28.904 million, which is about 9.05% of the company's issued shares excluding treasury shares [1] - The placement price represents a discount of approximately 12.04% from the closing price on the same day [1] Expected Net Proceeds - The estimated net proceeds from the placement are approximately HKD 240 million after deducting related expenses and costs [1] Use of Proceeds - About 45% of the net proceeds will be allocated for clinical research and trials related to localized fat accumulation management, hair diseases and care, skin diseases and care, and epidermal anesthesia pipeline [1] - Another 45% will be used for marketing activities, channel expansion, and brand building for CU-40102 (topical finasteride spray) and CU-10201 (topical 4% minocycline foam) [1] - Approximately 10% of the net proceeds will be utilized for working capital and other general corporate purposes [1]

格隆汇8月28日丨荣智控股(06080.HK)公告，于2025年8月28日，公司与配售代理订立配售协议，据此， 公司拟配售最多1.866亿股，配售股份相当于(i)公司于本公告日期现有已发行股本的约19.98%；及(ii)公 司经配发及发行所有配售股份扩大已发行股本的约16.66%。每股配售股份0.085港元，较股份于配售协 议日期在联交所所报收市价每股股份0.101港元折让约15.84%。 配售的最高所得款项净额将为约15.2百万港元，将用作营运资金及未来商机。 ...

配售事项的最高所得款项总额将约为297.0百万港元，而最高所得款项净额将约为293.7百万港元。配售 事项所得款项净额预期将悉数用于偿还集团借贷及用作集团一般营运资金。 格隆汇8月26日丨中泽丰(01282.HK)发布公告，于2025年8月26日，公司与配售代理订立配售协议，据 此，公司已有条件同意透过配售代理，按竭诚基准按每股配售股份0.128港元（较配售协议日期在联交 所所报收市价每股股份0.152港元折让约15.8%）的价格向不少于六名承配人配售最多23.2亿股配售股 份。 配售股份的最高数目相当于(i)本公告日期公司现有已发行股本约86.6%；及(ii)经配售事项扩大的公司已 发行股本约46.4%。 ...

最高所得款项净额将约为2.94亿港元。配售事项所得款项净额预期将悉数用于偿还集团借贷及用作集团 一般营运资金。 中泽丰(01282)发布公告，于2025年8月26日交易时段后，公司与配售代理订立配售协议，据此，公司已 有条件同意透过配售代理，按竭诚基准按每股配售股份0.128港元的价格向不少于六名承配人配售最多 23.2亿股配售股份。配售价较于配售协议日期在联交所所报的收市价每股股份0.152港元折让约15.8%。 ...

Core Viewpoint - The company has announced a placement agreement with a placement agent to issue up to 145 million shares at a price of HKD 0.415 per share, representing a discount of approximately 9.78% from the closing price of HKD 0.46 on August 21, 2025 [1] Group 1 - The placement is aimed at attracting at least six independent third-party subscribers [1] - If fully subscribed, the 145 million shares will account for about 6.34% of the company's enlarged issued share capital [1] - The total expected proceeds from the placement are approximately HKD 60.175 million, with net proceeds estimated at around HKD 58.825 million after deducting related expenses [1]

Group 1 - The company, WanGuo Gold Group (03939), has announced an agreement for a share placement involving the sale of 22.5 million shares at a price of HKD 32.55 per share [1][2] - The total number of shares being sold represents approximately 2.03% of the company's enlarged issued share capital post-subscription [2] - The subscription price reflects a discount of about 7.00% compared to the closing price of HKD 35.00 per share on August 20, 2025 [2] Group 2 - The estimated net proceeds from the subscription are approximately HKD 722 million after deducting professional fees and expenses [2] - The company intends to use the net proceeds for exploration and development projects related to the Jinling Mine, as well as for general working capital [2]

Market Overview - The Hang Seng Index (HSI) closed at 25,176 points, down 93 points or 0.4% after reaching a high of 25,466 points earlier in the day[1] - The total market turnover was HKD 312.78 billion, the highest level since July 31[1] - Northbound trading totaled HKD 181.83 billion, while southbound funds saw a net inflow of HKD 1.39 billion, a significant drop of 96% from last Friday's net inflow of HKD 35.88 billion[1] A-Shares Performance - The Shanghai Composite Index rose 31 points or 0.9% to close at 3,728 points, with a peak of 3,745 points, marking a nearly ten-year high[2] - The Shenzhen Component Index increased by 200 points or 1.7%, closing at 11,835 points, with a turnover of CNY 1.63 trillion[2] - The ChiNext Index gained 71 points or 2.8%, closing at 2,606 points, with a turnover of CNY 829.6 billion[2] Corporate Earnings Highlights - Wu Jinzi, the founder of WuXi AppTec (02268.HK), reported a revenue of CNY 2.701 billion for the six months ending June, a year-on-year increase of 62.2%[3] - The net profit for WuXi AppTec was CNY 746 million, up 52.7%, with earnings per share of CNY 0.62[3] - Genscript Biotech (01672.HK) announced a placement of 52.4 million shares at HKD 16.45, a discount of approximately 9.9% from the closing price[4] - Hansoh Pharmaceutical (03692.HK) reported a revenue of CNY 7.434 billion, a year-on-year increase of 14.3%, with a net profit of CNY 3.134 billion, up 15%[4] - Li Auto (09863.HK) achieved a revenue of CNY 24.25 billion, a year-on-year increase of 174.1%, turning a profit of CNY 33.03 million compared to a loss of CNY 2.212 billion in the previous year[5]